INDIANOLA, PA, - MEDRAD, INC. announces the availability of the 1.5T HD Neurovascular Array coil for use with GE Signa© 1.5T EXCITE^TM HDMR systems. The 1.5T HD (High Definition) Neurovascular Array coil is the only Neurovascular coil available that supports the Hypertronics connector to fully utilize the benefits of GE Signa 1.5T EXCITE HDMR technology. The HD Neurovascular Array coil will be sold exclusively through GE Healthcare.

The MEDRAD HD Neurovascular Array coil has been designed and tested to enable exceptional image quality in the head, neck, cervical spine, and upper chest.

"The 1.5T HD Neurovascular Array coil for GE EXCITE HDMR systems enables outstanding image quality with the highest signal-to-noise and uniformity that we have encountered for imaging of the brain and the vasculature in the head and neck", said Michael Wood, general manager, MR Research Collaboration, GE Healthcare. In addition, the coil supports unique open architecture with a pivoting anterior paddle to ensure full patient comfort.
MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and accessory products, and equipment services. Total 2004 revenues were $344 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is a U.S. affiliate of Schering AG, Germany (NYSE:SHR).

Cautionary Statement Regarding Forward-Looking Statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Medrad's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Medrad undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events, circumstances or otherwise.

Back to HCB News

More Industry Headlines